ANX1502
Complement-Mediated Diseases
Phase 1Active
Key Facts
About Annexon
Annexon is a leader in developing C1q-targeting monoclonal antibodies to inhibit the classical complement pathway, a key driver of inflammation and neurodegeneration. Founded on seminal research from Stanford neurobiology, the company has built a late-stage pipeline with lead programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA). Its strategy focuses on achieving functional benefits for patients by blocking complement activation upstream, potentially offering a more comprehensive and selective therapeutic profile than downstream inhibitors.
View full company profileTherapeutic Areas
Other Complement-Mediated Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Pozelimab | Regeneron | Phase 3 |
| mHam 2.0 – Complement-Dependent Cell Killing Assay | Machaon Diagnostics | Commercial |
| ADX-096 | Q32 Bio | Preclinical |
| C3d mAb fusions & nanobodies | Q32 Bio | Discovery |
| RLYB116 | Rallybio | Phase 1 |